Amgen (AMGN) Competitors

$339.30 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$340.28 +0.98 (+0.29%)

As of 05/22/2026 07:55 PM Eastern

AMGN vs. GILD, MRNA, VRTX, ABBV, and AZN

Should you buy Amgen stock or one of its competitors? MarketBeat compares Amgen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amgen include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), and Astrazeneca (AZN).

How does Amgen compare to Gilead Sciences?

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Gilead Sciences had 34 more articles in the media than Amgen. MarketBeat recorded 78 mentions for Gilead Sciences and 44 mentions for Amgen. Amgen's average media sentiment score of 1.08 beat Gilead Sciences' score of 0.91 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	37 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Gilead Sciences	44 Very Positive mention(s)	10 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.4%. Amgen pays out 70.1% of its earnings in the form of a dividend. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years and Gilead Sciences has raised its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has lower revenue, but higher earnings than Amgen. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.98	$7.71B	$14.37	23.61
Gilead Sciences	$29.44B	5.67	$8.51B	$7.34	18.31

Amgen has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Amgen currently has a consensus target price of $355.19, indicating a potential upside of 4.68%. Gilead Sciences has a consensus target price of $156.93, indicating a potential upside of 16.80%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Gilead Sciences has a net margin of 30.99% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Gilead Sciences	30.99%	48.19%	18.28%

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Amgen and Gilead Sciences tied by winning 10 of the 20 factors compared between the two stocks.

How does Amgen compare to Moderna?

Moderna (NASDAQ:MRNA) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Amgen had 28 more articles in the media than Moderna. MarketBeat recorded 44 mentions for Amgen and 16 mentions for Moderna. Amgen's average media sentiment score of 1.08 beat Moderna's score of -0.20 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Amgen	37 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 0.9% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, Amgen has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Amgen has a net margin of 20.96% compared to Moderna's net margin of -143.55%. Amgen's return on equity of 137.41% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Amgen	20.96%	137.41%	13.28%

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.57	-$2.82B	-$8.15	N/A
Amgen	$36.75B	4.98	$7.71B	$14.37	23.61

Moderna currently has a consensus price target of $35.73, indicating a potential downside of 23.78%. Amgen has a consensus price target of $355.19, indicating a potential upside of 4.68%. Given Amgen's stronger consensus rating and higher probable upside, analysts clearly believe Amgen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

Summary

Amgen beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Amgen compare to Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	9.19	$3.95B	$16.86	25.77
Amgen	$36.75B	4.98	$7.71B	$14.37	23.61

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Amgen	20.96%	137.41%	13.28%

In the previous week, Amgen had 18 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 44 mentions for Amgen and 26 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.39 beat Amgen's score of 1.08 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	21 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	37 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Amgen has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vertex Pharmaceuticals presently has a consensus target price of $555.17, suggesting a potential upside of 27.77%. Amgen has a consensus target price of $355.19, suggesting a potential upside of 4.68%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48

Summary

Vertex Pharmaceuticals beats Amgen on 10 of the 17 factors compared between the two stocks.

How does Amgen compare to AbbVie?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

76.5% of Amgen shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.9% of Amgen shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.98	$7.71B	$14.37	23.61
AbbVie	$61.16B	6.24	$4.23B	$2.03	106.41

Amgen has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
AbbVie	5.79%	-576.45%	13.39%

In the previous week, AbbVie had 27 more articles in the media than Amgen. MarketBeat recorded 71 mentions for AbbVie and 44 mentions for Amgen. AbbVie's average media sentiment score of 1.24 beat Amgen's score of 1.08 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	37 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	54 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen presently has a consensus price target of $355.19, indicating a potential upside of 4.68%. AbbVie has a consensus price target of $253.43, indicating a potential upside of 17.32%. Given AbbVie's stronger consensus rating and higher possible upside, analysts clearly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

Summary

AbbVie beats Amgen on 12 of the 20 factors compared between the two stocks.

How does Amgen compare to Astrazeneca?

Amgen (NASDAQ:AMGN) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.3%. Amgen pays out 70.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.98	$7.71B	$14.37	23.61
Astrazeneca	$58.74B	4.94	$10.23B	$6.66	28.11

76.5% of Amgen shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Astrazeneca	17.19%	30.86%	12.68%

In the previous week, Amgen had 33 more articles in the media than Astrazeneca. MarketBeat recorded 44 mentions for Amgen and 11 mentions for Astrazeneca. Amgen's average media sentiment score of 1.08 beat Astrazeneca's score of 0.37 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	37 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Astrazeneca	5 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Amgen currently has a consensus price target of $355.19, suggesting a potential upside of 4.68%. Astrazeneca has a consensus price target of $205.33, suggesting a potential upside of 9.66%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts clearly believe Astrazeneca is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Amgen beats Astrazeneca on 14 of the 20 factors compared between the two stocks.

Get Amgen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMGN vs. The Competition

Export

Metric	Amgen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$183.11B	$3.37B	$6.43B	$12.32B
Dividend Yield	2.97%	2.26%	2.76%	5.28%
P/E Ratio	23.61	18.91	21.01	25.66
Price / Sales	4.98	329.35	615.84	111.99
Price / Cash	10.04	125.17	43.49	56.67
Price / Book	19.92	7.09	10.37	7.14
Net Income	$7.71B	$24.45M	$3.57B	$335.98M
7 Day Performance	4.60%	5.45%	6.01%	3.56%
1 Month Performance	-1.52%	2.43%	3.52%	2.54%
1 Year Performance	24.90%	62.98%	34.13%	35.05%

Amgen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMGN Amgen	3.8923 of 5 stars	$339.30 flat	$355.19 +4.7%	+24.9%	$183.11B	$36.75B	23.61	31,500	Positive News Analyst Upgrade
GILD Gilead Sciences	4.6323 of 5 stars	$130.54 +0.0%	$156.93 +20.2%	+25.1%	$162.08B	$29.74B	17.78	17,000	Analyst Revision Gap Down
MRNA Moderna	1.2891 of 5 stars	$48.49 +6.0%	$35.73 -26.3%	+78.5%	$19.22B	$1.94B	N/A	4,700	Insider Trade
VRTX Vertex Pharmaceuticals	4.6043 of 5 stars	$429.36 -1.1%	$555.17 +29.3%	-0.3%	$108.94B	$12.00B	25.46	6,400	Positive News
ABBV AbbVie	4.9069 of 5 stars	$212.55 -0.6%	$253.43 +19.2%	+17.7%	$375.53B	$62.82B	104.71	57,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMGN) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amgen (AMGN) Competitors

AMGN vs. GILD, MRNA, VRTX, ABBV, and AZN

How does Amgen compare to Gilead Sciences?

Summary

How does Amgen compare to Moderna?

Summary

How does Amgen compare to Vertex Pharmaceuticals?

Summary

How does Amgen compare to AbbVie?

Summary

How does Amgen compare to Astrazeneca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMGN vs. The Competition

Amgen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amgen (AMGN) Competitors

AMGN vs. GILD, MRNA, VRTX, ABBV, and AZN

How does Amgen compare to Gilead Sciences?

Does the media refer more to AMGN or GILD?

Is AMGN or GILD a better dividend stock?

Which has stronger valuation & earnings, AMGN or GILD?

Which has more volatility & risk, AMGN or GILD?

Do analysts rate AMGN or GILD?

Is AMGN or GILD more profitable?

Do institutionals and insiders hold more shares of AMGN or GILD?

Summary

How does Amgen compare to Moderna?

Does the media refer more to MRNA or AMGN?

Do institutionals & insiders have more ownership in MRNA or AMGN?

Which has more volatility & risk, MRNA or AMGN?

Is MRNA or AMGN more profitable?

Which has higher earnings and valuation, MRNA or AMGN?

Do analysts rate MRNA or AMGN?

Summary

How does Amgen compare to Vertex Pharmaceuticals?

Which has stronger earnings and valuation, VRTX or AMGN?

Is VRTX or AMGN more profitable?

Does the media favor VRTX or AMGN?

Which has more risk and volatility, VRTX or AMGN?

Do insiders and institutionals hold more shares of VRTX or AMGN?

Do analysts prefer VRTX or AMGN?

Summary

How does Amgen compare to AbbVie?

Do insiders and institutionals hold more shares of AMGN or ABBV?

Which has better earnings and valuation, AMGN or ABBV?

Which has more volatility and risk, AMGN or ABBV?

Is AMGN or ABBV more profitable?

Does the media prefer AMGN or ABBV?

Is AMGN or ABBV a better dividend stock?

Do analysts rate AMGN or ABBV?

Summary

How does Amgen compare to Astrazeneca?

Is AMGN or AZN a better dividend stock?

Which has more risk & volatility, AMGN or AZN?

Which has stronger earnings & valuation, AMGN or AZN?

Do institutionals and insiders believe in AMGN or AZN?

Is AMGN or AZN more profitable?

Does the media refer more to AMGN or AZN?

Do analysts rate AMGN or AZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMGN vs. The Competition

Amgen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools